AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
ORLANDO, FLA. -- Chemotherapy followed by tamoxifen treatment in early breast cancer patients resulted in better disease-free survival than concurrent chemotherapy and tamoxifen, Dr. Kathy S. Albain said at the annual meeting of the American Society of Clinical Oncology.
Of 1,477 women who participated in the randomized, controlled trial (all of whom were postmenopausal, had axillary lymph node involvement, and had tumors with either estrogen or progesterone receptors), 566 were treated with 6 months of chemotherapy (cyclophosphamide, Adriamycin, and 5-fluorouracil) followed by 5 years of tamoxifen, she said. Six months of concurrent chemotherapy and tamoxifen, followed by tamoxifen alone for 5 years, were given to 550 women. Tamoxifen alone was given to 361 women.
The disease-free survival rate at 8-year follow-up was 67% in the sequential chemotherapy/tamoxifen group, 62% in the concurrent chemotherapy/tamoxifen group, and 55% in the ...
Source: HighBeam Research, Tamoxifen given after chemotherapy improves survival in early breast...